Wedbush Has Negative Forecast for TCRX FY2025 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Research analysts at Wedbush cut their FY2025 earnings per share (EPS) estimates for shares of TScan Therapeutics in a research report issued on Wednesday, March 5th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.98) per share for the year, down from their previous forecast of ($0.97). Wedbush currently has a "Outperform" rating and a $7.00 target price on the stock. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics' Q4 2025 earnings at ($0.22) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.96) EPS and FY2028 earnings at ($0.89) EPS.

A number of other equities research analysts have also recently issued reports on TCRX. Barclays dropped their price objective on TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a research note on Friday, March 7th. Needham & Company LLC lowered their price target on shares of TScan Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a report on Wednesday, March 5th. Finally, HC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of TScan Therapeutics in a report on Thursday, March 6th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $9.20.

TScan Therapeutics Stock Down 0.3 %

TCRX stock traded down $0.01 during midday trading on Monday, hitting $1.80. The company's stock had a trading volume of 177,273 shares, compared to its average volume of 314,161. TScan Therapeutics has a twelve month low of $1.71 and a twelve month high of $9.69. The stock has a market capitalization of $95.80 million, a P/E ratio of -1.69 and a beta of 0.91. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The company's fifty day moving average price is $2.34 and its 200 day moving average price is $3.92.

Remove Ads

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The firm had revenue of $0.67 million for the quarter, compared to analyst estimates of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%.

Institutional Investors Weigh In On TScan Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Checkpoint Capital L.P. acquired a new stake in shares of TScan Therapeutics during the 3rd quarter worth $4,110,000. abrdn plc raised its position in shares of TScan Therapeutics by 137.8% in the 4th quarter. abrdn plc now owns 883,704 shares of the company's stock valued at $2,686,000 after buying an additional 512,049 shares in the last quarter. State Street Corp lifted its holdings in shares of TScan Therapeutics by 24.4% during the 3rd quarter. State Street Corp now owns 756,499 shares of the company's stock worth $3,767,000 after acquiring an additional 148,414 shares during the period. Dimensional Fund Advisors LP increased its stake in TScan Therapeutics by 108.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company's stock valued at $851,000 after acquiring an additional 145,731 shares during the last quarter. Finally, Lynx1 Capital Management LP boosted its holdings in shares of TScan Therapeutics by 2.5% in the 4th quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company's stock valued at $16,286,000 after purchasing an additional 132,747 shares in the last quarter. Institutional investors and hedge funds own 82.83% of the company's stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.